Published in Infect Immun on March 19, 2007
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Cryptococcal interactions with the host immune system. Eukaryot Cell (2010) 1.57
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother (2012) 1.32
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Inheritance of immune polarization patterns is linked to resistance versus susceptibility to Cryptococcus neoformans in a mouse model. Infect Immun (2008) 1.22
Cryptococcus gattii isolates from the British Columbia cryptococcosis outbreak induce less protective inflammation in a murine model of infection than Cryptococcus neoformans. Infect Immun (2009) 1.18
The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J Immunol (2010) 1.15
Nonlytic exocytosis of Cryptococcus neoformans from macrophages occurs in vivo and is influenced by phagosomal pH. MBio (2011) 1.15
The intracellular life of Cryptococcus neoformans. Annu Rev Pathol (2013) 1.06
Intracellular pathogenic bacteria and fungi--a case of convergent evolution? Nat Rev Microbiol (2008) 1.06
Most environmental isolates of Cryptococcus neoformans var. grubii (serotype A) are not lethal for mice. Infect Immun (2009) 1.02
The interaction between Candida krusei and murine macrophages results in multiple outcomes, including intracellular survival and escape from killing. Infect Immun (2011) 0.98
Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei. PLoS One (2012) 0.98
The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol (2009) 0.98
Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection. Infect Immun (2008) 0.98
Antibody therapy for histoplasmosis. Front Microbiol (2012) 0.96
Cryptococcus neoformans: historical curiosity to modern pathogen. Yeast (2014) 0.94
Phenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host response. Infect Immun (2008) 0.90
Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection. J Immunol (2012) 0.90
Capsules from pathogenic and non-pathogenic Cryptococcus spp. manifest significant differences in structure and ability to protect against phagocytic cells. PLoS One (2012) 0.90
Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections. Mucosal Immunol (2014) 0.90
In vitro interactions of Candida parapsilosis wild type and lipase deficient mutants with human monocyte derived dendritic cells. BMC Microbiol (2011) 0.86
Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol (2012) 0.86
Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine (2011) 0.83
Generation of stable mutants and targeted gene deletion strains in Cryptococcus neoformans through electroporation. Med Mycol (2014) 0.83
Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans. Infect Immun (2009) 0.82
Experimental models of cryptococcosis. Int J Microbiol (2011) 0.81
Pulmonary responses to Stachybotrys chartarum and its toxins: mouse strain affects clearance and macrophage cytotoxicity. Toxicol Sci (2010) 0.81
Susceptibility to progressive Cryptococcus neoformans pulmonary infection is regulated by loci on mouse chromosomes 1 and 9. Infect Immun (2012) 0.80
Cryptococcus neoformans: Tripping on Acid in the Phagolysosome. Front Microbiol (2016) 0.78
Analysis of cell cycle and replication of mouse macrophages after in vivo and in vitro Cryptococcus neoformans infection using laser scanning cytometry. Infect Immun (2012) 0.78
The Cnes2 Locus on Mouse Chromosome 17 Regulates Host Defense against Cryptococcal Infection through Pleiotropic Effects on Host Immunity. Infect Immun (2015) 0.77
Overview of vertebrate animal models of fungal infection. J Immunol Methods (2014) 0.77
Identification and Functional Characterization of a Cryptococcus neoformans UPC2 Homolog. Mycobiology (2010) 0.76
New technology and resources for cryptococcal research. Fungal Genet Biol (2014) 0.76
ALL2, a Homologue of ALL1, Has a Distinct Role in Regulating pH Homeostasis in the Pathogen Cryptococcus neoformans. Infect Immun (2015) 0.75
Innate Immune Responses to Cryptococcus. J Fungi (Basel) (2017) 0.75
THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : I. THE QUANTITATIVE ASPECTS OF THE MOUSE PROTECTION TEST. J Exp Med (1935) 4.90
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
The damage-response framework of microbial pathogenesis. Nat Rev Microbiol (2003) 4.07
Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun (2000) 3.42
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
The contribution of melanin to microbial pathogenesis. Cell Microbiol (2003) 3.12
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J Immunol Methods (1992) 2.97
Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol (2006) 2.92
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J Exp Med (1991) 2.64
Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun (1987) 2.63
Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun (1998) 2.60
Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J Immunol (1990) 2.28
The immune response to fungal infections. Br J Haematol (2005) 2.24
T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect Immun (1991) 2.17
Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol (2000) 2.14
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun (1998) 2.12
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Intrapulmonary growth and dissemination of an avirulent strain of Cryptococcus neoformans in mice depleted of CD4+ or CD8+ T cells. J Exp Med (1991) 2.03
Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun (2004) 1.99
Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans. J Immunol (1989) 1.97
IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol (1998) 1.93
Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect Immun (1977) 1.93
Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun (1990) 1.89
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A (1993) 1.86
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J Immunol (2005) 1.81
Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol (2005) 1.80
Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun (1996) 1.71
IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol (1997) 1.71
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun (2004) 1.66
An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol (2005) 1.61
The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect Immun (2006) 1.60
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med (1997) 1.60
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Interferon-gamma activates rat alveolar macrophages for anticryptococcal activity. Am J Respir Cell Mol Biol (1991) 1.45
IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol (1996) 1.45
Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J Immunol (2001) 1.42
Experimental murine pulmonary cryptococcosis. Differences in pulmonary inflammation and lymphocyte recruitment induced by two encapsulated strains of Cryptococcus neoformans. Lab Invest (1994) 1.37
The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin Diagn Lab Immunol (1998) 1.37
CNLAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence. Infect Immun (2004) 1.36
Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur J Immunol (2003) 1.30
Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol (2002) 1.30
A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am J Respir Cell Mol Biol (1995) 1.28
Estimating the relative contributions of virulence factors for pathogenic microbes. Infect Immun (2006) 1.21
Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol (2005) 1.20
Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. J Immunol (2005) 1.18
Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol (1996) 1.17
The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infect Immun (2005) 1.15
Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Infect Immun (1998) 1.14
Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line. Microbes Infect (2006) 1.11
Capsule and melanin synthesis in Cryptococcus neoformans. Med Mycol (2001) 1.11
Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells. Infect Immun (2005) 1.11
Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect Immun (1995) 1.08
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect Immun (2004) 1.06
Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect Immun (2004) 1.03
Enhanced allergic inflammation and airway responsiveness in rats with chronic Cryptococcus neoformans infection: potential role for fungal pulmonary infection in the pathogenesis of asthma. J Infect Dis (2006) 1.00
Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J Immunol (2005) 1.00
Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans. Infect Immun (2001) 0.98
The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies. Curr Mol Med (2005) 0.93
Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococcus neoformans. Clin Exp Immunol (1997) 0.92
The relative susceptibility of New Zealand black and CBA mice to infection with opportunistic fungal pathogens. Sabouraudia (1976) 0.91
Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia (1999) 0.90
Decreased resistance to primary intravenous Cryptococcus neoformans infection in aged mice despite adequate resistance to intravenous rechallenge. Infect Immun (1998) 0.90
Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection. Biol Signals (1997) 0.89
Colonization and pathogenesis of Cryptococcus neoformans in gnotobiotic mice. Infect Immun (1987) 0.89
Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother (2001) 0.88
Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies. Infect Immun (2004) 0.87
Interferon gamma increases survival in murine experimental cryptococcosis. Rev Inst Med Trop Sao Paulo (1996) 0.83
Differential effect of Cryptococcus neoformans on the production of IL-12p40 and IL-10 by murine macrophages stimulated with lipopolysaccharide and gamma interferon. FEMS Microbiol Lett (1999) 0.83
Anti-CD11 b monoclonal antibody suppresses brain dissemination of Cryptococcus neoformans in mice. Microbiol Immunol (2002) 0.80
Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci U S A (2012) 5.89
Causes for the persistence of impact factor mania. MBio (2014) 3.77
Why has the number of scientific retractions increased? PLoS One (2013) 3.59
Retracted science and the retraction index. Infect Immun (2011) 3.35
The contribution of melanin to microbial pathogenesis. Cell Microbiol (2003) 3.12
Cryptococcosis. Infect Dis Clin North Am (2002) 3.01
Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol (2006) 2.92
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell (2006) 2.55
Public health and biosecurity. Adaptations of avian flu virus are a cause for concern. Science (2012) 2.52
Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell (2007) 2.42
NIH peer review reform--change we need, or lipstick on a pig? Infect Immun (2009) 2.21
Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother (2006) 2.12
The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem (2005) 2.07
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
Reforming science: methodological and cultural reforms. Infect Immun (2011) 1.85
The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect (2003) 1.84
CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity (2002) 1.83
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest (2011) 1.80
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.76
Vesicular transport in Histoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes. Cell Microbiol (2008) 1.73
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A (2003) 1.71
Ionizing radiation changes the electronic properties of melanin and enhances the growth of melanized fungi. PLoS One (2007) 1.70
Lost in translation--basic science in the era of translational research. Infect Immun (2009) 1.70
The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem (2007) 1.67
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell (2004) 1.64
The presence of female conveners correlates with a higher proportion of female speakers at scientific symposia. MBio (2014) 1.63
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. Proc Natl Acad Sci U S A (2010) 1.62
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol (2005) 1.61
Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest (2003) 1.60
Important science--it's all about the SPIN. Infect Immun (2009) 1.59
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
Ionizing radiation: how fungi cope, adapt, and exploit with the help of melanin. Curr Opin Microbiol (2008) 1.58
Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother (2002) 1.57
Global warming will bring new fungal diseases for mammals. MBio (2010) 1.56
Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog (2007) 1.55
Policy: Adaptations of avian flu virus are a cause for concern. Nature (2012) 1.54
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Vertebrate endothermy restricts most fungi as potential pathogens. J Infect Dis (2009) 1.51
Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol (2007) 1.51
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med (2004) 1.47
Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis (2006) 1.47
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Sec6-dependent sorting of fungal extracellular exosomes and laccase of Cryptococcus neoformans. Mol Microbiol (2008) 1.46
Synthesis and assembly of fungal melanin. Appl Microbiol Biotechnol (2011) 1.45
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect Immun (2003) 1.44
The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence (2011) 1.42
Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (2006) 1.42
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun (2005) 1.42
Microstructure of cell wall-associated melanin in the human pathogenic fungus Cryptococcus neoformans. Biochemistry (2005) 1.40
Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun (2010) 1.40
Experimental murine cryptococcal infection results in contamination of bedding with Cryptococcus neoformans. Contemp Top Lab Anim Sci (2003) 1.40
Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell (2007) 1.39
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med (2006) 1.38
A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun (2006) 1.38
The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol (2006) 1.37
Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol (2008) 1.36
Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell (2007) 1.36
Reforming science: structural reforms. Infect Immun (2011) 1.36
The radioprotective properties of fungal melanin are a function of its chemical composition, stable radical presence and spatial arrangement. Pigment Cell Melanoma Res (2008) 1.36
The capsular dynamics of Cryptococcus neoformans. Trends Microbiol (2006) 1.35
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol (2008) 1.32
Histoplasma capsulatum synthesizes melanin-like pigments in vitro and during mammalian infection. Infect Immun (2002) 1.31
Vesicle-associated melanization in Cryptococcus neoformans. Microbiology (2009) 1.31
Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol (2002) 1.30
Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur J Immunol (2003) 1.30
Mechanistic science. Infect Immun (2009) 1.29
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe (2013) 1.26
Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A (2004) 1.26
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun (2002) 1.24
Characterization of yeast extracellular vesicles: evidence for the participation of different pathways of cellular traffic in vesicle biogenesis. PLoS One (2010) 1.24
Males are overrepresented among life science researchers committing scientific misconduct. MBio (2013) 1.22
Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell Microbiol (2006) 1.22
Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell (2006) 1.21
Estimating the relative contributions of virulence factors for pathogenic microbes. Infect Immun (2006) 1.21
Quorum sensing in fungi--a review. Med Mycol (2012) 1.21
Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol (2005) 1.20
Synthesis of melanin-like pigments by Sporothrix schenckii in vitro and during mammalian infection. Infect Immun (2003) 1.19
Bioterrorism: lessons learned since the anthrax mailings. MBio (2011) 1.19
Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A (2009) 1.19
Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light. Appl Environ Microbiol (2007) 1.18
Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. PLoS One (2007) 1.17